Pericarditis Drugs Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2032
6.73%
CAGR (2026-2032)
4.34 USD Bn.
Market Size
324
Report Pages
165
Market Tables
Overview
Pericarditis Drugs Market size is expected to grow at a CAGR of 6.73% during the forecast period and the market size is expected to reach nearly USD 6.85 Bn. by 2032.
Pericarditis is an inflammation caused to the sac-like membrane surrounding the heart i.e. pericardium. Pericarditis is usually acute and may last up to several months. The inflammation causes chest pain and accumulation of fluid around the pericardium. Other symptoms include low-grade fever, increased heart rate, leg or abdominal swelling, cough, and shortness of breath.
To know about the Research Methodology:- Request Free Sample Report
Global Pericarditis Drugs Market Dynamics:
Increasing prevalence of cardiovascular diseases and pericarditis is expected to drive the demand for pericarditis drugs. According to the study done by the American heart association, the prevalence is high in men than women. Assimilation of pain management in the medicine domain, adoption of dual therapy for the treatment of pericarditis has fueled the growth of pericarditis drugs market.
Global Pericarditis Drugs Market Regional analysis:
North America dominates the global pericarditis drugs market.
North America held largest market share in 2025 due to high number of heart disease patients and high expenditure on R&D and healthcare. Market size in Europe was USD xx Mn. in 2025. Detailed analysis of European market in countries is given in the report with local market dynamics and healthcare opportunities for the investors.
The objective of the report is to present a comprehensive analysis of the Global Pericarditis Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Pericarditis Drugs Market dynamics, structure by analyzing the market segments and project the Global Pericarditis Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Pericarditis Drugs Market make the report investor’s guide.
Acute Pericarditis is the most common condition affecting the pericardium. It lasts for less than 6 weeks. Chest pain is the common symptom of acute pericarditis. Colchicine has proved an essential treatment in acute pericarditis.
Recent Industry Developments
| Exact Date | Company | Development | Impact |
|---|---|---|---|
| 24 February 2026 | Kiniksa Pharmaceuticals | The company reported that ARCALYST (rilonacept) achieved $677.6 million in full-year 2025 revenue, representing a 62% year-over-year growth in the recurrent pericarditis market. | Solidifies ARCALYST as a dominant biologic therapy, with 2026 revenue projected to reach up to $920 million. |
| 10 February 2026 | Cardiol Therapeutics | Publication of ARCHER Phase II results confirmed that CardiolRx significantly reduces myocardial inflammation, providing clinical validation for its ongoing pericarditis trial. | Strengthens the clinical rationale for using small-molecule inflammasome inhibitors as a non-immunosuppressive alternative in cardiac care. |
| 13 January 2026 | Cardiol Therapeutics | The company reached the 50% patient enrollment milestone for its pivotal Phase III MAVERIC trial evaluating CardiolRx for recurrent pericarditis. | Accelerates the timeline for a potential oral, non-immunosuppressive therapy to challenge the current biologic-heavy treatment landscape. |
| 17 October 2025 | Kiniksa Pharmaceuticals | The U.S. FDA granted Orphan Drug Designation to KPL-387 (abiprubart) for the treatment of pericarditis. | Provides regulatory incentives and market exclusivity potential for a next-generation monoclonal antibody targeting IL-1 receptor. |
| 05 June 2025 | Kiniksa Pharmaceuticals | Announced the trial design for the Phase 2/3 clinical trial of KPL-387 specifically for patients with recurrent pericarditis. | Establishes a strategic pipeline expansion aimed at providing monthly self-administered liquid formulations for long-term disease management. |
| 30 April 2025 | Kiniksa Pharmaceuticals | Launched a major patient awareness campaign, "Life DisRPted," featuring high-profile advocates to increase diagnosis of recurrent pericarditis. | Directly influences market demand by reducing the time to diagnosis and increasing the prescription rates for advanced therapies. |
Global Pericarditis Drugs Market Scope : Inquire before buying
| Pericarditis Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 4.34 USD Billion |
| Forecast Period 2026-2032 CAGR: | 6.73% | Market Size in 2032: | 6.85 USD Billion |
| Segments Covered: | by Drug-type | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Colchicine Corticosteroids Others |
|
| by Distribution channels | Hospital pharmacy Retail pharmacy Online pharmacy |
||
| by Disease | Acute pericarditis Chronic pericarditis Recurrent pericarditis Idiopathic pericarditis |
||
Pericarditis Drugs Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Players / Competitors Profiles Covered in Brief in Global Pericarditis Drugs Market Report in Strategic Perspective:
- Pfizer Inc.
- Bayer AG
- Kiniksa Pharmaceuticals
- AstraZeneca PLC
- Johnson & Johnson
- XYMAS Pharmaceutical
- Hikma pharmaceutical
- Cigna
- Swedish Orphan Biovitrum AB (Sobi)
- Takeda Pharmaceutical Co Ltd
- Merck & Co. Inc
- Novartis AG
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Zydus Lifesciences Limited
- Camber Pharmaceuticals Ltd
- Alchem International Pvt. Ltd
- Sarv Biolabs Pvt. Ltd
- Midas Pharma GmbH
- AdvaCare Pharma
- Actavis GmbH
- Enomark LLC
- Honour Lab Limited
Table of Contents
1. Pericarditis Drugs Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Pericarditis Drugs Market: Competitive Landscape
2.1. MMR Competition Matrix
2.2. Competitive Landscape
2.3. Key Players Benchmarking
2.3.1. Company Name
2.3.2. Business Segment
2.3.3. End-user Segment
2.3.4. Revenue (2025)
2.3.5. Company Locations
2.4. Leading Pericarditis Drugs Market Companies, by market capitalization
2.5. Market Structure
2.5.1. Market Leaders
2.5.2. Market Followers
2.5.3. Emerging Players
2.6. Mergers and Acquisitions Details
3. Pericarditis Drugs Market: Dynamics
3.1. Pericarditis Drugs Market Trends by Region
3.1.1. North America Pericarditis Drugs Market Trends
3.1.2. Europe Pericarditis Drugs Market Trends
3.1.3. Asia Pacific Pericarditis Drugs Market Trends
3.1.4. Middle East and Africa Pericarditis Drugs Market Trends
3.1.5. South America Pericarditis Drugs Market Trends
3.2. Pericarditis Drugs Market Dynamics by Region
3.2.1. North America
3.2.1.1. North America Pericarditis Drugs Market Drivers
3.2.1.2. North America Pericarditis Drugs Market Restraints
3.2.1.3. North America Pericarditis Drugs Market Opportunities
3.2.1.4. North America Pericarditis Drugs Market Challenges
3.2.2. Europe
3.2.2.1. Europe Pericarditis Drugs Market Drivers
3.2.2.2. Europe Pericarditis Drugs Market Restraints
3.2.2.3. Europe Pericarditis Drugs Market Opportunities
3.2.2.4. Europe Pericarditis Drugs Market Challenges
3.2.3. Asia Pacific
3.2.3.1. Asia Pacific Pericarditis Drugs Market Drivers
3.2.3.2. Asia Pacific Pericarditis Drugs Market Restraints
3.2.3.3. Asia Pacific Pericarditis Drugs Market Opportunities
3.2.3.4. Asia Pacific Pericarditis Drugs Market Challenges
3.2.4. Middle East and Africa
3.2.4.1. Middle East and Africa Pericarditis Drugs Market Drivers
3.2.4.2. Middle East and Africa Pericarditis Drugs Market Restraints
3.2.4.3. Middle East and Africa Pericarditis Drugs Market Opportunities
3.2.4.4. Middle East and Africa Pericarditis Drugs Market Challenges
3.2.5. South America
3.2.5.1. South America Pericarditis Drugs Market Drivers
3.2.5.2. South America Pericarditis Drugs Market Restraints
3.2.5.3. South America Pericarditis Drugs Market Opportunities
3.2.5.4. South America Pericarditis Drugs Market Challenges
3.3. PORTER's Five Forces Analysis
3.4. PESTLE Analysis
3.5. Technology Roadmap
3.6. Regulatory Landscape by Region
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Middle East and Africa
3.6.5. South America
3.7. Key Opinion Leader Analysis For Pericarditis Drugs Industry
3.8. Analysis of Government Schemes and Initiatives For Pericarditis Drugs Industry
3.9. Pericarditis Drugs Market Trade Analysis
3.10. The Global Pandemic Impact on Pericarditis Drugs Market
4. Pericarditis Drugs Market: Global Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
4.1. Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
4.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
4.1.2. Colchicine
4.1.3. Corticosteroids
4.1.4. Others
4.2. Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
4.2.1. Hospital pharmacy
4.2.2. Retail pharmacy
4.2.3. Online pharmacy
4.3. Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
4.3.1. Acute pericarditis
4.3.2. Chronic pericarditis
4.3.3. Recurrent pericarditis
4.3.4. Idiopathic pericarditis
4.4. Pericarditis Drugs Market Size and Forecast, by Region (2025-2032)
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. Middle East and Africa
4.4.5. South America
5. North America Pericarditis Drugs Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
5.1. North America Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
5.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.2. Colchicine
5.1.3. Corticosteroids
5.1.4. Others
5.2. North America Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
5.2.1. Hospital pharmacy
5.2.2. Retail pharmacy
5.2.3. Online pharmacy
5.3. North America Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
5.3.1. Acute pericarditis
5.3.2. Chronic pericarditis
5.3.3. Recurrent pericarditis
5.3.4. Idiopathic pericarditis
5.4. North America Pericarditis Drugs Market Size and Forecast, by Country (2025-2032)
5.4.1. United States
5.4.1.1. United States Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
5.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.4.1.1.2. Colchicine
5.4.1.1.3. Corticosteroids
5.4.1.1.4. Others
5.4.1.2. United States Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
5.4.1.2.1. Hospital pharmacy
5.4.1.2.2. Retail pharmacy
5.4.1.2.3. Online pharmacy
5.4.1.3. United States Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
5.4.1.3.1. Acute pericarditis
5.4.1.3.2. Chronic pericarditis
5.4.1.3.3. Recurrent pericarditis
5.4.1.3.4. Idiopathic pericarditis
5.4.2. Canada
5.4.2.1. Canada Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
5.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.4.2.1.2. Colchicine
5.4.2.1.3. Corticosteroids
5.4.2.1.4. Others
5.4.2.2. Canada Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
5.4.2.2.1. Hospital pharmacy
5.4.2.2.2. Retail pharmacy
5.4.2.2.3. Online pharmacy
5.4.2.3. Canada Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
5.4.2.3.1. Acute pericarditis
5.4.2.3.2. Chronic pericarditis
5.4.2.3.3. Recurrent pericarditis
5.4.2.3.4. Idiopathic pericarditis
5.4.3. Mexico
5.4.3.1. Mexico Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
5.4.3.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.4.3.1.2. Colchicine
5.4.3.1.3. Corticosteroids
5.4.3.1.4. Others
5.4.3.2. Mexico Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
5.4.3.2.1. Hospital pharmacy
5.4.3.2.2. Retail pharmacy
5.4.3.2.3. Online pharmacy
5.4.3.3. Mexico Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
5.4.3.3.1. Acute pericarditis
5.4.3.3.2. Chronic pericarditis
5.4.3.3.3. Recurrent pericarditis
5.4.3.3.4. Idiopathic pericarditis
6. Europe Pericarditis Drugs Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
6.1. Europe Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.2. Europe Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.3. Europe Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4. Europe Pericarditis Drugs Market Size and Forecast, by Country (2025-2032)
6.4.1. United Kingdom
6.4.1.1. United Kingdom Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.1.2. United Kingdom Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.1.3. United Kingdom Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.2. France
6.4.2.1. France Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.2.2. France Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.2.3. France Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.3. Germany
6.4.3.1. Germany Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.3.2. Germany Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.3.3. Germany Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.4. Italy
6.4.4.1. Italy Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.4.2. Italy Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.4.3. Italy Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.5. Spain
6.4.5.1. Spain Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.5.2. Spain Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.5.3. Spain Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.6. Sweden
6.4.6.1. Sweden Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.6.2. Sweden Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.6.3. Sweden Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.7. Austria
6.4.7.1. Austria Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.7.2. Austria Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.7.3. Austria Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
6.4.8.2. Rest of Europe Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
6.4.8.3. Rest of Europe Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7. Asia Pacific Pericarditis Drugs Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
7.1. Asia Pacific Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.2. Asia Pacific Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.3. Asia Pacific Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4. Asia Pacific Pericarditis Drugs Market Size and Forecast, by Country (2025-2032)
7.4.1. China
7.4.1.1. China Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.1.2. China Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.1.3. China Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.2. S Korea
7.4.2.1. S Korea Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.2.2. S Korea Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.2.3. S Korea Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.3. Japan
7.4.3.1. Japan Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.3.2. Japan Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.3.3. Japan Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.4. India
7.4.4.1. India Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.4.2. India Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.4.3. India Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.5. Australia
7.4.5.1. Australia Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.5.2. Australia Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.5.3. Australia Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.6. Indonesia
7.4.6.1. Indonesia Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.6.2. Indonesia Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.6.3. Indonesia Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.7. Malaysia
7.4.7.1. Malaysia Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.7.2. Malaysia Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.7.3. Malaysia Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.8. Vietnam
7.4.8.1. Vietnam Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.8.2. Vietnam Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.8.3. Vietnam Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.9. Taiwan
7.4.9.1. Taiwan Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.9.2. Taiwan Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.9.3. Taiwan Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
7.4.10. Rest of Asia Pacific
7.4.10.1. Rest of Asia Pacific Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
7.4.10.2. Rest of Asia Pacific Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
7.4.10.3. Rest of Asia Pacific Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
8. Middle East and Africa Pericarditis Drugs Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
8.1. Middle East and Africa Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
8.2. Middle East and Africa Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
8.3. Middle East and Africa Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
8.4. Middle East and Africa Pericarditis Drugs Market Size and Forecast, by Country (2025-2032)
8.4.1. South Africa
8.4.1.1. South Africa Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
8.4.1.2. South Africa Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
8.4.1.3. South Africa Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
8.4.2. GCC
8.4.2.1. GCC Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
8.4.2.2. GCC Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
8.4.2.3. GCC Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
8.4.3. Nigeria
8.4.3.1. Nigeria Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
8.4.3.2. Nigeria Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
8.4.3.3. Nigeria Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
8.4.4. Rest of ME&A
8.4.4.1. Rest of ME&A Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
8.4.4.2. Rest of ME&A Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
8.4.4.3. Rest of ME&A Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
9. South America Pericarditis Drugs Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
9.1. South America Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
9.2. South America Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
9.3. South America Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
9.4. South America Pericarditis Drugs Market Size and Forecast, by Country (2025-2032)
9.4.1. Brazil
9.4.1.1. Brazil Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
9.4.1.2. Brazil Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
9.4.1.3. Brazil Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
9.4.2. Argentina
9.4.2.1. Argentina Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
9.4.2.2. Argentina Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
9.4.2.3. Argentina Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
9.4.3. Rest Of South America
9.4.3.1. Rest Of South America Pericarditis Drugs Market Size and Forecast, by Drug-type (2025-2032)
9.4.3.2. Rest Of South America Pericarditis Drugs Market Size and Forecast, by Distribution channels (2025-2032)
9.4.3.3. Rest Of South America Pericarditis Drugs Market Size and Forecast, by Disease (2025-2032)
10. Company Profile: Key Players
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Scale of Operation (small, medium, and large)
10.1.7. Details on Partnership
10.1.8. Regulatory Accreditations and Certifications Received by Them
10.1.9. Awards Received by the Firm
10.1.10. Recent Developments
10.2. Bayer AG
10.3. Kiniksa Pharmaceuticals
10.4. AstraZeneca PLC
10.5. Johnson & Johnson
10.6. XYMAS Pharmaceutical
10.7. Hikma pharmaceutical
10.8. Cigna
10.9. Swedish Orphan Biovitrum AB (Sobi)
10.10. Takeda Pharmaceutical Co Ltd
10.11. Merck & Co. Inc
10.12. Novartis AG
10.13. Bristol-Myers Squibb Company
10.14. Teva Pharmaceutical Industries Ltd
10.15. Sun Pharmaceutical Industries Ltd
10.16. Aurobindo Pharma Limited
10.17. Zydus Lifesciences Limited
10.18. Camber Pharmaceuticals Ltd
10.19. Alchem International Pvt. Ltd
10.20. Sarv Biolabs Pvt. Ltd
10.21. Midas Pharma GmbH
10.22. AdvaCare Pharma
10.23. Actavis GmbH
10.24. Enomark LLC
10.25. Honour Lab Limited
11. Key Findings
12. Industry Recommendations
13. Pericarditis Drugs Market: Research Methodology
14. Terms and Glossary